Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Thirteen and thirty-nine weeks ended March 3, 2007 (Fiscal 2007 Period).
Business Overview: AngioDynamics designs, develops, manufactures, and markets medical devices for minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD) and oncology. The company operates in a single segment.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | 13 Weeks Ended Mar 3, 2007 | 39 Weeks Ended Mar 3, 2007 | 39 Weeks Ended Feb 25, 2006 |
|---|---|---|---|
| Net Sales | $26,738 | $71,372 | $54,859 |
| Gross Profit | $15,949 (59.7% margin) | $42,119 (59.0% margin) | $31,914 (58.2% margin) |
| Operating (Loss) Profit | $(20,084) | $(15,257) | $7,202 |
| Net (Loss) Income | $(16,405) | $(12,053) | $4,828 |
| Diluted EPS | $(0.88) | $(0.73) | $0.37 |
| Cash Flow from Operations | N/A | $3,437 | $4,736 |
| Total Assets | $377,280 | N/A | N/A |
| Total Liabilities | $46,014 | N/A | N/A |
| Stockholders' Equity | $331,266 | N/A | N/A |
Liquidity and Debt:
- Cash and cash equivalents: $38,052 (down from $64,042 at June 3, 2006).
- Total Debt: $17.5 million (comprised of $7.8 million in bank debt for facility expansion and $9.7 million in convertible notes assumed in the RITA acquisition).
- Current Ratio: 7.7 to 1.
Material Changes vs. Prior Period
- Acquisition of RITA Medical Systems: Completed on January 29, 2007. This transaction significantly altered the financial structure, adding $169.6 million in goodwill and $12.1 million in purchased R&D charges. RITA's results are included from the acquisition date.
- Revenue Growth: Net sales increased 35.1% in the quarter and 30.1% for the 39-week period compared to the prior year, driven by new product launches and the inclusion of RITA sales.
- Operating Expenses: Operating expenses surged due to the acquisition. General and Administrative expenses increased 615.8% in the quarter, and R&D expenses increased 885.3%, primarily due to the $12.1 million in-process R&D charge and a $9.6 million litigation charge.
- Profitability: The company reported a net loss for the current periods compared to net income in the prior year, driven by non-recurring acquisition costs and litigation charges.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items:
- In-Process R&D Charge: $12.1 million recorded related to the RITA acquisition (non-deductible for tax purposes).
- Litigation Charge: $9.6 million recorded in General and Administrative expenses related to an unfavorable jury verdict in Diomed v. AngioDynamics (awarded damages of $8.36 million plus interest/fees). The company intends to appeal.
- Stock-Based Compensation: $2.4 million expense recognized for the 39-week period following the adoption of SFAS 123(R).
Outlook and Management Commentary:
- Management expects international sales to increase significantly due to RITA's global presence.
- Gross margins are expected to improve due to RITA's historically higher margins.
- The company is pursuing the acquisition of Oncobionic, Inc., contingent on successful human use tests expected within 12 months. A $5.0 million non-refundable deposit has been paid.
Risks and Contingencies:
- Legal Proceedings: Ongoing patent infringement litigation with Diomed (verdict pending appeal) and VNUS Medical Technologies (trial set for October 2007). Indemnification from supplier biolitec is in dispute.
- Debt Covenants: The company failed to meet certain financial covenants related to its facility financing due to the R&D and litigation charges; however, the bank has waived noncompliance.
- Integration Risks: Risks associated with integrating RITA's operations, including retaining key employees and coordinating systems.
Investor Verification Checklist
- Appeal Status: Verify the outcome of the appeal regarding the $8.36 million Diomed verdict and the status of indemnification claims against biolitec.
- Oncobionic Acquisition: Monitor the results of the human use tests for irreversible electroporation (IRE) technology, which are a condition precedent for the $20 million remaining purchase price.
- Debt Covenants: Confirm continued compliance with financial covenants on the $5 million facility notes and the $9.7 million convertible notes.
- Non-GAAP Reconciliation: Review the reconciliation of GAAP net loss to "Adjusted Income" ($8.6 million for the 39-week period) to understand the impact of excluding acquisition and litigation costs.
- Goodwill Impairment: Assess the $169.6 million goodwill recorded from the RITA acquisition for potential future impairment risks if integration synergies are not realized.